Quantum Genesis AI Corp. Responds to OTC Markets Caveat Emptor Designation

Quantum Genesis AI Corp. has issued a statement regarding the Caveat Emptor designation placed on the Company's securities by OTC Markets Group, Inc. on February 12, 2026. Since the designation was applied, the Company has made several attempts to communicate with OTC Markets to better understand the basis for the designation and determine what steps may be necessary to address the matter. OTC Markets has indicated that the designation relates to a public interest concern, prompting the Company to request additional clarification while intending to continue cooperating with OTC Markets.

The Company recently received information from OTC Markets that it may formally request a review of the Caveat Emptor designation beginning March 13, 2026. Quantum Genesis AI intends to engage with OTC Markets at the earliest available opportunity to initiate that review process. Chief Executive Officer Naveen Kulkarni stated that the Company takes this matter seriously and is committed to working constructively with OTC Markets to better understand the basis for the designation. The objective is to obtain clarity regarding the matter and take any appropriate steps necessary as the Company moves through the review process.

This development matters because Caveat Emptor designations can significantly impact investor confidence and trading activity for companies listed on OTC markets. The designation serves as a warning to investors about potential concerns with a company's public information or trading activity. For Quantum Genesis AI, addressing this designation is crucial for maintaining market credibility and ensuring continued access to capital markets. The Company's response demonstrates its commitment to regulatory compliance and transparency, which are essential factors for investor protection in speculative markets.

The implications of this announcement extend beyond the immediate regulatory concern. How Quantum Genesis AI handles this situation could affect its ability to attract future investment and maintain relationships with current shareholders. The Company's statement emphasizes its intention to cooperate fully with OTC Markets, suggesting a proactive approach to resolving regulatory issues. This matters because companies facing such designations must navigate complex regulatory landscapes while maintaining shareholder trust. The outcome of the review process could influence how other OTC-listed companies approach similar regulatory challenges in the future.

Quantum Genesis AI remains committed to maintaining transparency with its shareholders and the broader investment community throughout this process. The Company intends to continue cooperating with OTC Markets and will provide updates as additional information becomes available. For more information, investors can visit the Company's website at https://www.qgaicorp.com and the Company's profile at https://www.otcmarkets.com/stock/QGAI. The situation highlights the importance of regulatory compliance for companies operating in emerging technology sectors where investor interest may be high but information transparency remains critical.